期刊文献+

首发精神分裂症患者利培酮治疗前后外周血浆蛋白质组学观察 被引量:4

Proteomic analysis of novel serum markers in first-episode schizophrenics before versus aftertreatment of risperidone
原文传递
导出
摘要 目的观察精神分裂症患者利培酮治疗前后外周血浆中蛋白质表达的变化,寻求潜在疾病诊断、治疗及药物不良反应相关的标志物。方法收集来自2011年1—12月于郑州大学第一附属医院就诊的80例首发精神分裂症患者,单一利培酮治疗8周。于治疗前及治疗8周末检测血脂、血糖,抽取晨空腹外周血分离血浆,选取15例患者血浆经过二维凝胶电泳(2-DE)、MALDI-TOF质谱分析并与蛋白质数据库对比确定差异表达的蛋白质,并应用ELISA检测所有样本差异表达蛋白质的变化。结果15例患者治疗前后蛋白质的表达量相差1.2倍以上共计23个。质谱分析后得出治疗后载脂蛋白A1(APOA-1)等9个蛋白质表达上调,触珠蛋白(HP)等8个蛋白质表达下调。所有患者ELISA结果显示,APOA-1及HP水平治疗前[APOA.1:(4.72±0.03)ng/ml;HP:(56.66±0.13)ng/ml]与治疗后[APOA-1:(5.14±0.06)ng,/ml;HP:(55.18±0.17)ng/ml]相比差异有统计学意义(P〈0.01)。结论治疗后外周血中血脂代谢及免疫相关的蛋白质发生改变,为临床医生根据这些血浆蛋白的变化监测抗精神病药物的不良反应提供了理论依据。 Objective To explore the changes in serum protein levels of schizophrenics before and after treatment of risperidone and identify the potential markers of diagnosis, treatment and drug side effects of schizophrenia. Methods Eighty first-episode schizophrenics without other concurrent diseases and with positive and negative symptom scale (PANSS) score greater than or equal to 60 were recruited. And 15 of them were measured by proteomics. Different serum levels of proteins were obtained from these patients and were separated by two-dimensional electrophoresis (2-DE) before and after a single risperidone treatment for 8 weeks. These proteins were then identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and peptide mass fingerprinting. Enzyme-linked immunosorbent assay (ELISA) was used to verify the resuhs. Results Almost 1400 spots were detected by 2-DE in each gel. Of these proteins, 23 protein spots showed significant differences in abundance before and after risperidone treatment. After MALDI-TOF peptide mass fingerprinting, 9 up-regulated proteins and 8 down-regulated proteins were validated after treatment. Of these proteins, the schizophrenics showed a significantly higher content of apolipoprotein A-1 ( APOA-1 ) than those before treatment and haptoglobin (HP) protein was down-regulated after treatment. The results of ELISA were parallel with those of proteomic ( P 〈 0.01 ). Conclusion The serum proteins correlated with blood glucose and lipid metabolism are altered in schizophrenia after treatment of risperidone. A clinician should monitor the side effects of antipsychotic drugs according to the changes of serum proteins.
出处 《中华医学杂志》 CAS CSCD 北大核心 2012年第45期3194-3198,共5页 National Medical Journal of China
基金 国家自然科学基金(30971058、81071090) 郑州大学研究生科学研究基金(11Y03309)
关键词 蛋白质组学 精神分裂症 利哌立酮 代谢 Proteomics Schizophrenia Risperidone Metabolism
  • 相关文献

参考文献22

  • 1Wildgust H J, Hodgson R, Beary M. The paradox of premature mortality in schizophrenia : new research questions. J Psychopharmacol, 2010, 24:9-15.
  • 2栾中山,许鹏,迟强.非典型抗精神病药物在临床上的应用[J].中国医药指南,2010,8(34):46-48. 被引量:15
  • 3Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry, 1999, 156:1686-1696.
  • 4Wirshing DA, Spellberg B J, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry, 1998, 44:778-783.
  • 5Yang L, Wang K, Chen J, et al. Exploring off-targets and off- systems for adverse drug reactions via chemical-protein interaetome--elozapine-induced agranulocytosis as a ease study.PLoS Comput Biol, 2011,7 : 1-13.
  • 6Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic- induced weight gain: insights into mechanisms of action. CNS Drugs, 2011,25:1035-1059.
  • 7Wen F, Tan J. Effects of phenothiazine drugs on serum levels of apolipoproteins and lipoproteins in schizophrenic subjects. Acta Pharmacol Sin, 2003, 24 : 1001-1005.
  • 8Venkatasubramanian G, Arasappa R, Rao NP, et al. Inverse relationship between serum high density lipoprotein and negative syndrome in antipsyehotic-naive schizophrenia. Clin Chem Lab Med, 2010, 48:95-98.
  • 9Martins-De-Souza D, Wobrock T, Zerr I, et al. Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D- isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry, 2010, 11:719- 728.
  • 10Eubanks JH, Djabali M, Selleri L, et al. Structure and linkage of the ]32 dopamine receptor and neural cell adhesion molecule genes on human chromosome 11q23. Genomics, 1992, 14:1010-1018.

共引文献14

同被引文献45

  • 1王家祥,张蛟,刘秋亮,王利,范应中,余捷凯,郑树.基于支持向量机对肾母细胞瘤患者血清蛋白质标记物的检测分析[J].中华医学杂志,2006,86(42):2982-2985. 被引量:8
  • 2Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics, 2007,4 : 51455.
  • 3Cortese JD, Voglino AL, Hackenbrock CR. Persistence of cytochrome c binding to membranes at physiological mitochondrial intermembrane space ionic strength. Biochim Biophys Acta,1995, 1228 : 216-228.
  • 4Sawai H, Domae N. Release of cytochrome c from mitochondria precedes Bax translocatiotl/activation in Triton X-100-induced apoptosis. Leuk Res, 2008, 32: 445-453.
  • 5Ito A, Uehara T, Tokumitsu A, et al. Possible involvement of cytochrome c release and sequential activation of caspases in ceramide-indnced apoptosis in SK-N-MC cells. Biochim Biophys Acta, 1999, 1452: 263-274.
  • 6Barczyk K, Kreuter M, Pryjma J, et al. Serum cytochromec indicates in vivo apoptosis and can serve as a prognostic markerdming cancer therapy. Int J Cancer, 2005,116 : 167-173.
  • 7Liu X, Kim CN, Yang J, et al. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell , 1996,86 : 147-157.
  • 8Adachi N, Hirota M, Hamaguchi M, et al. Serum cytochrome c level as a prognostic indicator in patients with systemic inflanunatory response syndrome. Clin Chim Acta, 2004, 342: 127-136.
  • 9Ben-Ari Z, Schmilovotz-Weiss H, Belinki A, et al. Circulating soluble cytochrome c in liver disease as a marker of apoptosis. J Intern Med ,2003,254: 168-175.
  • 10Renz A, Berdel WE, Kreuter M, et al. Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood ,2001,98: 1542-1548.

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部